Stockwinners Market Radar for October 23, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:49 EDT Quanterix announces new agreement to advance blood-based Alzheimer's detection - Quanterix (QTRX) "announced the signing of a license agreement with Janssen Sciences Ireland UC, a Johnson & Johnson (JNJ) Company. Under this agreement, Quanterix will receive worldwide, non-exclusive rights to J&J's extensively studied p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products, further strengthening Quanterix's position at the forefront of the Alzheimer's Disease biomarker field. Under the terms of the license agreement, Janssen will grant Quanterix a worldwide non-exclusive license for J&J-developed technology to produce Simoa p-Tau 217 research-use only assay kits for global distribution. Furthermore, under the agreement Quanterix will launch a Laboratory Developed Test based on the J&J p-Tau 217 antibodies and assay, offered through Accelerator under the Lucent Diagnostics brand. These advances mark a significant milestone for Quanterix's continued leadership in advancing Alzheimer's Disease diagnosis and treatment, providing a path for the first scalable immunoassay-based p-Tau 217 test to potentially become widely available to researchers and clinicians."

20:05 EDT Cathie Wood's ARK Investment bought 277.8K shares of Verve Therapeutics today

18:31 EDT Infinite Acquisition to redeem all Class A ordinary shares - Infinite Acquisition announced that its board of directors has determined to redeem all of its issued and outstanding Class A ordinary shares, par value 0.001c, effective as of November 6, because the Company will not consummate an initial business combination within the time required by its Amended and Restated Memorandum and Articles of Association, as extended in connection with the Company's extraordinary general meeting of shareholders held on August 22. The redemption of the Shares is expected to be completed on or around November 6, or ten business days followingthe Company's extension deadline on October 23. The per-share redemption price for the Shares, will be approximately $10.78. The balance of the Trust Account as of October 23, 2023 and following the redemptions effectuated in connection with the Extension Meeting was approximately $86,375,237, including interest and dividend income. In accordance with the terms of the related trust agreement, the Company expects to retain $100,000 of the interest and dividend income from the Trust Account to pay dissolution expenses. The Company anticipates that the Shares will cease trading on the NYSE as of the close of business on October 23.

17:31 EDT Biora Therapeutics to submit updated IND application for BT-600 - Biora Therapeutics announced an update regarding its Investigational New Drug application. The IND application supports the next phase of development of BT-600, a drug/device combination designed to use Biora's NaviCap(TM) ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis. "Near the end of the review period, the FDA requested additional information on our IND for BT-600 and will need additional time to complete review of our submission. We plan to address the agency's questions and submit our updated filing, potentially as early as this week," said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics. "We continue to have a constructive exchange with the FDA, and while we cannot predict their response, we anticipate remaining on track with our previously communicated execution timeline," continued Dr. Kelman. The IND application for BT-600 includes extensive manufacturing, preclinical, human device function, and toxicology data to support a first-in-human clinical trial for BT-600. The phase 1 trial of BT-600 is expected to be a randomized, double-blind, placebo-controlled study to evaluate safety, pharmacokinetics and pharmacodynamics, including effects on colon tissue, in healthy volunteers receiving the NaviCap device filled with a novel liquid formulation of tofacitinib at 5 mg and 10 mg doses. The NaviCap device has been designed for targeted delivery directly to the colon in this application.

16:59 EDT Sealed Air CEO Ted Doheny steps down - Sealed Air announced that its board of directors and Ted Doheny have mutually agreed to transition the company's leadership. Doheny has stepped down as president and CEO and as a member of the board, effective immediately. He will continue to serve SEE in an advisory capacity to assist in the transition. Effective immediately, Emile Chammas, COO, and Dustin Semach, CFO, are appointed interim co-presidents and co-CEOs, in addition to their current roles. The board is undertaking a comprehensive search, internally and externally, with the assistance of an executive search firm to identify SEE's next CEO.

16:45 EDT Accenture exec sells $1.57M in common stock - In a regulatory filing, Accenture disclosed that its Chief HR Officer Ellyn Shook sold 5,250 shares of common stock on October 20th in a total transaction size of $1.57M.

16:38 EDT Sovos Brands, Campbell Soup receive second request for information from FTC - In a regulatory filing, Sovos Brands (SOVO) disclosed that on October 23, the company and Campbell Soup (CPB) each received a request for additional information, or the "Second Request," from the U.S. Federal Trade Commission in connection with the FTC's review of the transactions contemplated by the companies' previously announced merger agreement. "Issuance of the Second Request extends the waiting period under the HSR Act until 30 days after both the company and Campbell substantially comply with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The company and Campbell have been working cooperatively with the FTC and will continue to do so. The company now expects that the Merger will close in 2024, and the company will continue to engage with the FTC on its review with the objective of closing the Merger in mid-2024," the filing stated.

16:33 EDT Ascent Solar receives decision from DOE regarding DE-FOA-0003057 concept paper - Ascent Solar announced that the initial concept paper submitted for DE-FOA-0003057: Bipartisan Infrastructure Law: Silicon Solar Manufacturing, and Dual-use Photovoltaics Incubator has been reviewed and received an "Encouraged" decision from the Department of Energy, or DOE. Ascent will now move forward with the application process in hopes of securing funding through this FOA to advance the development of the proposed agrivoltaic system. Ascent is working to innovate agrivoltaic technologies that will directly benefit the farmers of America by enabling reliable and durable on-site solar power generation for behind the meter use.

16:29 EDT Cadence Design falls 5% to $229.03 after Q3 results, below-consensus Q4 guidance

16:17 EDT Simpson Manufacturing sees FY23 CapEx about $100M - The company has updated its 2023 financial outlook based on three quarters of financial information to reflect its latest expectations regarding demand trends, raw material costs and operating expenses. Based on business trends and conditions as of today, October 23, 2023, the company's outlook for the full fiscal year ending December 31, 2023 is as follows: Operating margin is now estimated to be in the range of 22.0% to 22.5%. The effective tax rate is estimated to be in the range of 25% to 26%, including both federal and state income tax rates and assuming no tax law changes are enacted. Capital expenditures are estimated to be approximately $100M depending on a number of various external factors. The company continues to make progress on its efforts to integrate ETANCO into its operations and to realize previously identified offensive and defensive synergies in the years ahead. However, the company expects these efforts will result in ongoing integration costs through 2023 and beyond.

16:15 EDT Calix says 'excited about the growth opportunity ahead' - Calix said in its quarterly letter to investors: "We are excited about the growth opportunity ahead for Calix and our strategically aligned customers. Calix is partnering with BSPs to transform and disrupt the broadband industry through the power of our unique end-to-end platform and growing ecosystem of managed services business model to deliver offerings across residential, business, education and the communities they serve... Our financial strength is unmatched in the industry, with expanding revenue and margins, growing cash generation and a pristine balance sheet. We will continue to invest in our business, developing and deploying the platforms and managed services that are enabling our customers to add subscribers at a faster pace and achieve their business goals. The opportunity ahead of us is immense, and we are confident that we will maintain quarter-on-quarter revenue growth and margin expansion in a predictable manner."

16:10 EDT Mereo BioPharma received $9M milestone payment from Ultragenyx in July - As of September 30 the Company had cash and short-term deposits of GBP 51.2M or $62.4M. Cash and short-term deposits, net of expenditures, increased by GBP 9.1M or $11.1M during the third quarter of 2023. In July 2023, the Company received a $9M milestone payment from its partner, Ultragenyx, and gross proceeds of $12.0 million from the issuance of 9,673,419 ADSs representing 48,367,095 ordinary shares through an "at-the-market" offering pursuant to its Open Market Sale Agreement with Jefferies . The Company expects its existing cash and short-term deposits, excluding income from existing or potential partnerships, will enable it to fund its currently committed clinical trials, operating expenses and capital expenditure requirements into 2026.

16:08 EDT TrueBlue names Greg Netolicky as Chief People Officer - TrueBlue "announced that Greg Netolicky has joined the company as Chief People Officer, reporting directly to President and Chief Executive Officer, Taryn Owen. Netolicky has more than 20 years of experience across all aspects of human resources, spanning Fortune 500 and privately held organizations. Most recently, he served as the Chief Human Resources Officer for Rite-Hite Holding Company, a global manufacturing company."

16:07 EDT Mereo BioPharma provides update on recent program developments - Mereo BioPharma Group (MREO) provided an update on recent program developments and third quarter 2023 financial information. On October 14, 2023, Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma Group plc announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab achieved a 67% reduction in annualized fracture rate in patients with osteogenesis imperfecta with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries...Additionally, University of Alabama at Birmingham and the Company are reporting on the ATALANTa study, a multi-center, double-blind, placebo-controlled, proof-of-concept investigator-led study run by Professor Mark Dransfield, Director of the Division of Pulmonary, Allergy and Critical Care, UAB, in collaboration with Mereo...

16:03 EDT Herc Holdings narrows FY23 adjusted EBITDA view to $1.45B-$1.50B - Prior guidance was $1.45B-$1.55B

15:42 EDT Moody's, Google Cloud partner over generative AI applications - Moody's Corporation (MCO) and Google Cloud (GOOG) announced a new strategic partnership to explore bringing together Moody's expertise in financial analysis and Google Cloud's advanced generative AI technologies to help Moody's customers and employees leverage new large language models to glean new financial insights and summarize financial data faster. The partnership is premised on three core objectives: Building LLMs to Accelerate Financial Analysis: Powered by Google Cloud's gen AI platform, Vertex AI, and leveraging Moody's unique analytical expertise, Moody's and Google will explore co-creation of fine-tuned LLMs purpose-built for financial professionals, enabling customers to perform faster, deeper analyses of financial reports, disclosures and other materials. For example, customers will be able to interrogate, analyze, and draw decision-ready insight directly from financial disclosures. Enabling Access to Moody's Data in BigQuery for Financial Insights: Moody's will enable access to its proprietary datasets through BigQuery, Google Cloud's serverless data warehouse, which helps customers manage, query, and analyze data. This integration will allow customers to combine Moody's vast databases with their native data assets, and use them in combination with LLMs in Vertex AI. Customers will be able to build and access AI models, accelerating time-to-value through increased efficiency and individualized use cases for financial services professionals. Enhancing Enterprise Search for Financial Data: Moody's will introduce Vertex AI Search to increase efficiencies by automating manual workflows and combining multiple data sets for easier summation, deeper insights, and overall improved productivity.

15:08 EDT Intel down 3% after report says Nvidia plans to make PC CPUs - Shares of Intel (INTC) are down $1.16, or 3%, to $33.76 after Reuters reported, citing sources, that Nvidia (NVDA) has begun designing central processing units, or CPUs, that would run Microsoft's (MSFT) Windows operating system and use technology from Arm Holdings (ARM). Advanced Micro Devices (AMD) also plans to make chips for PCs with Arm technology, added the report, citing people familiar with the matter.

13:45 EDT Bakkt collaborates with Lightspark over UMA support - Bakkt announced that it is supporting a new open standard for money transmission: Universal Money Addresses or "UMAs." Bakkt has collaborated with Lightspark to be one of its initial partners, and is announcing the alpha launch of its UMA-capable Lightning service. This new service can be leveraged for cross-border remittances, B2B settlement, instantaneous deposits and withdrawals for trading, or global, interoperable P2P. "By leveraging our institutional-grade custody platform, best execution liquidity, fiat onramps, money transmission licensing, compliance infrastructure, and now Lightning service, we believe Bakkt is uniquely positioned to serve as the secure and reliable platform powering payments, remittances, P2P transfers, and on and off-ramps in the United States," the company said. "We are excited to enable this for our clients as together we tear down silos of value in the same way the Internet tore down silos of information." Reference Link

12:30 EDT Infinite Acquisition Corp trading halted, news pending

12:13 EDT Hasbro, Marvel expand relationship to bring characters to Magic: The Gathering - Hasbro announced an expansion of its long-standing relationship with Marvel. Together, Hasbro and Marvel will develop collectible products and tentpole sets for the trading card game, Magic: The Gathering. The first tentpole Magic set based on Marvel's characters and epic stories will appear globally in 2025, with additional all-new sets for multi-generational fans to collect and play, the companies said. "Trading cards have always been a part of Marvel's DNA, so this collaboration takes that experience to a whole new level," said Dan Buckley, President of Marvel Comics and Franchise. "With the depth that our storytelling and characters bring to the table, we can't wait for fans to see how the Marvel Universe translates seamlessly into gameplay within these Magic: The Gathering products and sets for years to come."

12:00 EDT FMC Corporation falls -11.7% - FMC Corporation is down -11.7%, or -$7.85 to $59.10.

12:00 EDT Mueller Industries falls -49.9% - Mueller Industries is down -49.9%, or -$35.16 to $35.29.

12:00 EDT Twin Ridge Capital Acquisition rises 16.3% - Twin Ridge Capital Acquisition is up 16.3%, or $1.12 to $8.01.

11:33 EDT BioNTech presents Phase 1/2 data update for BNT211 in advanced solid tumors - BioNTech announced follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company's Claudin-6-directed CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors. The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac. At the ESMO Congress 2023 in Madrid, Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute, Amsterdam, Netherlands presented the data in an oral late-breaking data session which confirms the positive interim data presented at this year's American Society of Clinical Oncology Annual Meeting in Chicago, USA. The data update included 44 patients who received CLDN6 CAR-T cells at four dose levels alone or in combination with CARVac. Patients with germ cell tumors, ovarian cancer and other solid tumor types were treated. In course of the dose escalation, a dose-dependent increase in adverse events was observed, with cytokine release syndromes occurring in 23 of 44 safety evaluable patients. In most cases, these were of grade 1 and 2, with one patient with a grade 3 and one with a grade 4 event. Neurotoxicity was mild and self-limiting in two patients. Of the total 44 patients, 38 were efficacy evaluable. The overall response rate for these 38 patients was 45% and the disease control rate 74%. Further, 27 patients were treated with CLDN6 CAR-T cells at dose level 2 with or without CARVac. At this dose level, 13 patients showed partial responses resulting in an ORR of 59% and a DCR of 95%. Additionally, in the same cohort, patients who received CARVac showed a prolonged persistence of CAR-T cells. These results further underline the potential of BioNTech's BNT211 program. One objective of the ongoing Phase 1/2 trial is to determine the recommended dose for the initiation of a potential pivotal Phase 2 trial in patients with germ cell tumors which is expected to be initiated in 2024.

11:02 EDT Focus Financial Partners appoints Dan Glaser as interim CEO - Focus Financial Partners announced that Dan Glaser, Chairman of Focus' Board of Directors and Operating Partner at Focus' majority investment partner, Clayton, Dubilier & Rice, has been appointed the Company's Interim CEO. He succeeds Rudy Adolf, who will begin handing over responsibilities immediately and retire at the end of the year, after successfully founding the company. The Focus Board has initiated a search for a new CEO.

10:40 EDT AstraZeneca says Dato-DXd improved progression-free survival in NSCLC trial - AstraZeneca (AZN) and Daiichi Sankyo's (DSNKY) datopotamab deruxtecan, or Dato-DXd, reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors in a trial, the companies announced. Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan demonstrated a statistically significant improvement for the primary endpoint of progression-free survival, or PFS, compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, treated with at least one prior line of therapy, the companies stated. These data will be shared today in the second of two late-breaking presentations for datopotamab deruxtecan in a Presidential Symposium at the European Society for Medical Oncology, or ESMO, 2023 Congress in Madrid, Spain.

10:35 EDT AstraZeneca reports 'positive' results from TROPION-Breast01 Phase III trial - AstraZeneca (AZN) says "positive" results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan, or Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, compared to investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. These data will be shared today in the first of two late-breaking presentations for datopotamab deruxtecan in a Presidential Symposium at the European Society for Medical Oncology, or ESMO, 2023 Congress in Madrid, Spain. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate, or ADC, being jointly developed by AstraZeneca and Daiichi Sankyo (DSNKY).

10:33 EDT Novartis reports Phase III PSMAfore trial with Pluvicto met primary endpoint - Novartis presented data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology, or ESMO, Congress. Data presented at the Presidential Symposium showed that Pluvicto met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival, or rPFS, in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, or mCRPC, after treatment with androgen receptor pathway inhibitor therapy, compared to a change in ARPI. The trial met its primary endpoint of rPFS with a 59% reduction in the risk of radiographic disease progression in patients with Pluvicto versus a change of ARPI. Using a data cut off with a median of 8.6 months longer study follow-up, an updated rPFS analysis demonstrated a consistent clinical benefit in patients with Pluvicto versus a change in ARPI, more than doubling time to radiographic disease progression, the company stated. "These promising results from PSMAfore could change the treatment paradigm for advanced prostate cancer by allowing patients to potentially avoid or delay taxane-based chemotherapy, which carries a heavy burden of side effects. While data collection for overall survival continues, the consistency of the benefit observed on other clinically meaningful efficacy endpoints, together with improved quality of life and favorable safety profile, show the potential of Pluvicto for taxane-naive patients with mCRPC," said Jeff Legos, Executive Vice President, Global Head of Oncology Development at Novartis.

10:01 EDT Vertex announces strategic partnership with Pagero - Vertex has announced at its 2023 Vertex Exchange conference a partnership with Pagero, a global network leader for the exchange of invoices and other business documents. The partnership enables a seamless solution that allows businesses to ensure continuous indirect tax compliance and bring efficiencies to their invoicing lifecycle, all within a single cloud platform. Vertex e-Invoicing, partnering with Pagero, simplifies indirect tax compliance and streamlines Continuous Transaction Controls requirements. The joint offering enables tax, finance and IT departments direct access to data for CTC, unlocks e-invoice clearance, real-time reporting and Peppol access for electronic B2B and B2G compliant document and data exchange.

10:00 EDT Great Ajax falls -28.1% - Great Ajax is down -28.1%, or -$1.79 to $4.58.

10:00 EDT EngageSmart rises 11.5% - EngageSmart is up 11.5%, or $2.33 to $22.53.

10:00 EDT Textainer rises 43.9% - Textainer is up 43.9%, or $14.98 to $49.13.

09:54 EDT Tesla says DOJ requests information related to Autopilot, FSD features - In a regulatory filing, Tesla said: "We receive requests for information from regulators and governmental authorities, such as the National Highway Traffic Safety Administration, the National Transportation Safety Board, the SEC, the Department of Justice and various local, state, federal and international agencies. We routinely cooperate with such regulatory and governmental requests, including subpoenas, formal and informal requests and other investigations and inquiries. For example, the SEC had issued subpoenas to Tesla in connection with Elon Musk's prior statement that he was considering taking Tesla private. The take-private investigation was resolved and closed with a settlement entered into with the SEC in September 2018 and as further clarified in April 2019 in an amendment. The SEC also has periodically issued subpoenas to us seeking information on our governance processes around compliance with the SEC settlement, as amended. Separately, the company has received requests for information, including subpoenas, from the DOJ. These have included requests for documents related to Tesla's Autopilot and FSD features. Additionally, the company has received requests for information, including subpoenas from the DOJ, regarding certain matters associated with personal benefits, related parties, vehicle range and personnel decisions. To our knowledge no government agency in any ongoing investigation has concluded that any wrongdoing occurred. We cannot predict the outcome or impact of any ongoing matters. Should the government decide to pursue an enforcement action, there exists the possibility of a material adverse impact on our business, results of operation, prospects, cash flows, financial position or brand."

09:47 EDT Great Ajax falls -21.0% - Great Ajax is down -21.0%, or -$1.34 to $5.03.

09:47 EDT Mueller Industries falls -50.3% - Mueller Industries is down -50.3%, or -$35.41 to $35.04.

09:47 EDT EngageSmart rises 11.9% - EngageSmart is up 11.9%, or $2.40 to $22.60.

09:46 EDT AKA Brands trading halted, volatility trading pause

09:33 EDT Damon Motors announces reverse merger with Inpixon, plans Nasdaq listing - Damon Motors, makers of the HyperSport electric motorcycle, is pleased to announce it has signed a definitive agreement with Inpixon to complete a reverse merger with a proposed spin-off entity of Inpixon, Grafiti Holding. Grafiti's assets will consist of Inpixon Ltd., a division of Inpixon's data analytics and statistical visualization solutions business, based in the United Kingdom, following the contribution of such assets from Inpixon to Grafiti. Damon's HyperSport is expected to be one of the safest, smartest and most powerful motorcycles available in the market. Damon has received more than $70M in funding to date and has secured more than $85M in pre-production, consumer reservations for its motorcycles. The enterprise value of Damon was ascertained by Inpixon's independent financial advisory firm to be within the range of $224M and $284M. In connection with the Business Combination, Grafiti will effect a spinoff of all the outstanding capital stock of Grafiti to the holders of Inpixon's outstanding capital stock and certain other securityholders as of a record date to be determined. Following the Spin-off, Damon will acquire Grafiti by way of a three-cornered amalgamation under a statutory plan of arrangement in British Columbia, pursuant to which Damon and a newly-formed, wholly-owned subsidiary of Grafiti will amalgamate and form a continuing entity, which will be wholly owned by Grafiti. Pursuant to the amalgamation, Grafiti will acquire all of the issued and outstanding Damon Shares and will issue Grafiti Shares to the holders of Damon Shares as consideration therefor, after which the legacy Damon shareholders and Grafiti shareholders are expected to hold 81.25% and 18.75%, respectively, of the outstanding Grafiti Shares on a fully diluted basis. Upon the completion of the Business Combination, the combined company will be listed on the Nasdaq Capital Market, subject to the approval of an initial listing application. The Business Combination has been approved unanimously by the Board of Directors of both Inpixon and Damon.

09:29 EDT CEL-SCI presents data for immunotherapy drug Multikine at ESMO - CEL-SCI Corporation announced that it has finalized the selection criteria for the head and neck cancer target population to be treated with the Company's immunotherapy drug Multikine or Leukocyte Interleukin, Injection . Five-year survival in the target population was 73% alive for Multikine-treated patients vs only 45% alive in the control who did not receive Multikine, with the five-year risk of death cut in half for Multikine-treated subjects in the target population versus the control. These data, which are statistically significant and accompanied by strong hazard ratios, are a crucial achievement on the path for the approval of Multikine. CEL-SCI presented the data for the first time at the European Society for Medical Oncology ESMO Congress in Spain on October 22 . The selection criteria for this target population were developed based on the completed Phase 3 randomized controlled trial, advice from regulators, and advice from physician consultants associated with the University of California San Diego Cancer Center and Yale Medical School, recognized as among the nation's most esteemed immuno-oncologists in head and neck cancer.

09:21 EDT Academy Sports promotes Sam Johnson to President - Academy Sports announced that Sam Johnson, Executive VP of Retail Operations, will become President, succeeding Michael Mullican, who is stepping down to pursue other personal and professional opportunities. Johnson has served as EVP of Retail Operations and a member of the executive leadership team since joining Academy in April 2017. Prior to joining the company, Johnson spent seven years with hhgregg, where he most recently served as Chief Retail Officer and led various functions including store operations, customer relations, commercial sales, real estate and visual merchandising. Prior to hhgregg, he spent more than 20 years in various leadership roles with Sears Holdings Corporation, including Vice President of Small Stores. Eric Friederich has been promoted to Senior VP of Retail Operations, succeeding Johnson as the head of store operations. Friederich has been with Academy since November 2016, most recently as Regional Vice President of East Region Stores and previously as Senior Director of Communication and Merchandise Execution and as a District Manager.

09:19 EDT Fathom Digital appoints Carey Chen as CEO - Fathom Digital announced that its board of directors has appointed Carey Chen as CEO of the company. Chen will succeed Ryan Martin, effective immediately. Chen has served as a member of Fathom's board since the company became publicly listed in 2021 and served as a director of Fathom's predecessor companies dating back to 2019. Prior to being appointed CEO of Fathom, Chen served as the president of Altix Corporation, a management consulting firm serving a broad array of industrial manufacturing companies.

09:17 EDT Senmiao Technology reports September operating metrics for ride-hailing platform - Senmiao Technology announced the operating metrics for its proprietary online ride-hailing platform for the month of September. In September 2023, Senmiao and its affiliates recorded 0.61 million total completed orders, compared to 0.62 million total orders completed in August 2023. The decrease was primarily the result of a decreased number of completed orders from partner platforms under the new model, which was partially offset by an increased number of completed orders by Senmiao's own platform through Gaode under the original model, as the Guangzhou compliance check to Gaode's platform has been completed. Since the launch of Senmiao's online ride-hailing platform in October 2020, more than 25.0 million rides have been completed using its own platform. Over 8.8 million rides have been completed on several platforms in partnership with Senmiao since August 2021.

09:12 EDT Pearl selects Verisk's data, analytics to streamline insurance delivery - Pearl Holding is harnessing LightSpeed from Verisk to help improve control and save money within its agent distribution channel. PHG provides affordable auto insurance to the nonstandard market using Verisk's LightSpeed for Personal Auto. By bringing pivotal underwriting analytics forward in a single data payload, LightSpeed can streamline workflows and help provide reliable quotes to consumers in seconds. "Delivering a robust data payload at the front end of the process is a cost-effective strategy that can help insurers to harness automated workflows, quickly segment risk, and improve the agent experience," said Joe Wodark, vice president of auto insurance underwriting solutions at Verisk. "With Verisk's technology and pricing flexibility, PHG is lowering its cost per acquisition while helping more consumers obtain coverage quickly and easily."

09:09 EDT Presto Automation signs voice AI pilot with top 10 QSR drive-thru brand - Presto Automation has signed new pilot agreements with two top major quick-service restaurant brands. One of Presto's new pilot drive-thru customers is a Top 10 QSR chain, ranked by annual revenues of restaurants that include a drive-thru concept, while the other is part of a leading global restaurant franchising company that manages over 2,000 locations in total. In both cases, Presto is now the only Voice AI vendor in an active pilot after two prior voice AI vendors failed to perform adequately beyond a pilot stage. "As an enterprise-grade solution, Presto Voice(TM) has demonstrated it is the best choice for large QSR chains," said Xavier Casanova, CEO of Presto. "Our unparalleled strength in technology development and our ability to roll out large-scale implementations in the restaurant industry sets Presto apart, and recent customer contracts and growth of installed locations tangibly illustrates Presto's leadership in the industry."

09:08 EDT Deluxe, IBM Consulting enter strategic collaboration - Deluxe (DLX) and IBM Consulting (IBM) announced a strategic collaboration aimed at transforming the receivables and cash application processing landscape for corporations. This collaboration has resulted in a joint go-to-market agreement intended to empower clients with a solution targeting the lifeblood of every business - optimizing cash flow. The primary focus of this collaboration is to put the power of receivables automation and cash application processing directly into the hands of corporations, help reduce overhead, and help increase overall efficiency. IBM Consulting, with its deep expertise in finance business process outsourcing services, is joining forces with Deluxe to bring joint clients an end-to-end solution that addresses both technology and operations.

09:07 EDT Check Point enhances global services with new managed securities capabilities - Check Point Software Technologies announces an important enhancement to its Check Point Infinity Global Services suite. New enhancements to Infinity Global Services: New Managed Network Security Service; New Managed Cloud Security Service; Extended Managed Detection and Response Capabilities. "Given the dynamic threat landscape, our focus is on ensuring our customers and partners are equipped with leading-edge managed security and cloud services," said Eitan Lugassi-Gilad, VP, Infinity Global Services at Check Point Software Technologies. "This expansion enhances our services offering, while strengthening Check Point's role as a key player in delivering managed security services. We are proud to help customers of all sizes address the complex challenges of designing and implementing a cyber-resiliency strategy and the nuances of cloud migrations for enterprises."

09:06 EDT American Energy Partners signs LOI for reverse merger with SCWorx - American Energy Partners announced it has signed a Letter of Intent to be acquired by SCWorx Corp, a Nasdaq listed company under the ticker symbol "WORX." The LOI sets forth the proposed terms and conditions pursuant to which SCWorx and American Environmental intend to effect a business combination, as a result of which American Environmental and SCWorx's healthcare data management business will each be conducted through wholly-owned subsidiaries of SCWorx. SCWorx anticipates that the Proposed Transaction will be structured as a share-for-share exchange, with SCWorx shareholders retaining 17% and American Environmental retaining 83% of the issued and outstanding shares of common stock of SCWorx, after giving effect to a $6 million capital raise by American Environmental, which is a condition to completion of the Proposed Transaction. The LOI has binding and non-binding components. The binding components require among other things that American Environmental provide SCWorx $150,000 of working capital, as well as cover its costs to complete the Proposed Transaction. In addition, both parties are restricted from engaging in discussions with other parties about an acquisition or other transaction similar to the terms of the Proposed Transaction. Upon execution of a definitive agreement, SCWorx will file a Current Report on Form 8-K with more details regarding the Proposed Transaction, including the proposed capitalization of SCWorx upon the closing of the Proposed Transaction. SCWorx previously engaged Stanton Park Capital, a boutique investment bank, to advise it in connection with the process of reviewing strategic opportunities available to SCWorx, including the Proposed Transaction. The Proposed Transaction has been approved by the Boards of Directors of both SCWorx and American Environmental and is expected to close in the first quarter of 2024. The Proposed Transaction will be structured either as a stock for stock exchange, in which American Environmental becomes a wholly owned subsidiary of SCWorx post-closing, or as a "reverse triangular merger," in which a subsidiary of SCWorx will merge with and into American Environmental, with American Environmental being the surviving entity. Because SCWorx will issue more than 20% of the issued and outstanding shares of its common stock to the shareholders of American Environmental in the Proposed Transaction, SCWorx must obtain approval from its stockholders in order to issue the shares in the Proposed Transaction pursuant to Rule 5635(d) of The Nasdaq Stock Market LLC. In addition, the closing of the Proposed Transaction is subject to satisfaction of the following conditions: satisfactory completion of due diligence review by both parties, the negotiation, execution, and delivery of the definitive agreement and any related agreements thereto, American Environmental raising $6 million of equity, concurrently with the closing, satisfactory completion of an audit of American Environmental's financial statements, approval of the final terms of the Proposed Transaction by the Board of Directors of SCWorx and American Environmental, and approval by American Environmental shareholders, as well as other customary closing conditions. There can be no assurance that the Proposed Transaction will be completed as currently contemplated, or at all.

09:04 EDT ImmunityBio announces resubmissionof N-803 or Anktiva BLA to FDA - ImmunityBio announced it has completed the resubmission of its Biologics License Application BLA to the U.S. Food and Drug Administration FDA for N-803 Anktiva , a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guerin BCG for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease. The BLA is supported by the results of ImmunityBio's studies in bladder cancer including the pivotal QUILT-3.032 study published in NEJM Evidence1 in November 2022. An update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease was provided in the BLA resubmission. This update demonstrated a prolonged duration of remission in responding subjects, with a median duration of CR not yet reached with a follow-up in responders exceeding 28 months, and a safety profile as reported previously. The updated duration of CR in these responding BCG-unresponsive subjects showed that the probability of maintaining a CR for = 24 months was 60%, with a cystectomy free rate at = 24 months of over 90%. I Of the 6 subjects available for follow-up 6 out of 6 subjects demonstrated long-term complete remission with bladder preservation over a median survival period of 8.8 years and all 6 subjects have avoided a cystectomy to date.

09:03 EDT Outfront Media to sell Canadian business to Bell Media for C$410M in cash - Outfront Media (OUT) and Bell Media announced that they have entered into an agreement to sell the Canadian business of OUTFRONT Media to Bell Media, a wholly-owned subsidiary of BCE (BCE). The purchase price is C$410M in cash, subject to certain adjustments and a holdback. The transaction is expected to close in 2024, subject to regulatory approval and other closing conditions. As of December 31, 2022, Outfront Media's Canadian business operated 9,325 total displays in the country and generated revenues of $91.9M during that year.

09:02 EDT Data Storage launches strategic sales, marketing initiative - Data Storage announced that it has launched a strategic sales and marketing initiative designed to capitalize on the growing demand for its products and services. "We are excited to launch this new sales and marketing initiative as we are witnessing a growing demand for our solutions that we intend to capitalize on," commented Chuck Piluso, CEO of Data Storage Corporation. "As part of our strategy, we have hired multiple new sales representatives who are dedicated to driving and securing new clients, allowing us to capitalize on our effective lead generation program underway, as well as progress discussions with potential clients on our nurture list. In addition, and equally important, is our new Major Accounts program. This program is focused on increasing our penetration within existing enterprise and middle-market accounts, in order to take advantage of up-selling and cross-selling opportunities. We believe these strategic initiatives will allow us to secure additional high-margin subscription-based contracts with high-profile clients across various industries. We look forward to realizing the benefits from these hires and new programs, which we believe will further enhance our growth."

09:01 EDT Castor Maritime announces sale of M/V Magic Sun, M/V Magic Phoenix - Castor Maritime announces that on October 6, 2023 and October 16, 2023, respectively, the Company entered into two separate agreements with two unaffiliated third parties for the sale of the M/V Magic Sun, a 2001-built Panamax bulk carrier vessel, for a price of $6.55 million and M/V Magic Phoenix, a 2008-built Panamax bulk carrier vessel, for a price of $14.0 million. Both vessels are expected to be delivered to their new owners during the fourth quarter of 2023. The Company expects to record during the fourth quarter of 2023 a net gain of approximately $1.0 million from the sale of the M/V Magic Sun, excluding any transaction-related costs, and a net loss of approximately $2.6 million from the sale of the M/V Magic Phoenix, excluding any transaction-related costs.

09:00 EDT Inpixon trading resumes

08:53 EDT Rockwell Automation to acquire Verve Industrial Protection, terms undisclosed - Rockwell Automation announced it has signed a definitive agreement to acquire Verve Industrial Protection, a cybersecurity software and services company that focuses specifically on industrial environments, expanding the offerings of Rockwell with an industry-leading asset inventory system and vulnerability management solution. The acquisition is subject to customary approvals and is expected to close in the first quarter of Rockwell's fiscal year 2024. At close, Verve will report into Rockwell's Lifecycle Services operating segment.

08:43 EDT Siyata Mobile enters distribution agreement with GetWireless - Siyata Mobile has entered into a distribution agreement for its SD7 handsets and accessories with GetWireless, a value-added distributor of cellular solutions that connect the Internet of Things. GetWireless has decades of experience working exclusively with channel partners in the IoT, mobility, in-building connectivity, fleet tracking and other wireless markets. It engages strategically with its partners to provide programs that fit numerous business models and facilitates top reseller programs.

08:40 EDT Magdalena Biosciences initiates preclinical study to evaluate plant extracts - Jaguar Health announced that Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and Filament Health, to develop novel, natural prescription medicines derived from plants for mental health indications, has initiated a preclinical study in Brazil to evaluate two plant extracts for their potential to treat depression, anxiety, attention-deficit/hyperactivity disorder and other possible neuropsychiatric conditions initially in adults. Analysis of the FDG PET scans will be done by Dr. Eduardo A. Zimmer of the Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil. The Zimmer Lab is comprised of a multidisciplinary team with expertise in conducting refined non-invasive imaging studies in small animals and humans. Dr. Elaine Elisabetsky, who has general responsibility for coordinating resources and principal investigators for this project in Brazil, is one of the world's leading ethnopharmacologists. She is a consultant to both Magdalena Biosciences and Jaguar and is a member of the scientific strategy team for Jaguar's Entheogen Therapeutics Initiative. Identification of plants best suited for these studies were done as part of the ETI, which aims to discover and develop groundbreaking, novel, natural medicines derived from psychoactive plants for treatment of mood disorders, neurodegenerative diseases, addiction, and other mental health disorders. The Magdalena Biosciences joint venture emerged from Jaguar's ETI.

08:37 EDT Alarum's NetNut launches new website to enhance marketing, sales capacity - Alarum Technologies announced that NetNut, its wholly owned subsidiary, launched its new website. The new website is expected to enhance NetNut's sales and marketing reach, providing easy, fast and user-friendly access to its variety of solutions. "We are thrilled to introduce our enhanced website, designed with our users in mind. This upgrade reflects our commitment to providing a seamless and engaging online experience. Our goal is to make it easier than ever for our online users to access the information they need, connect with our brand, and explore the valuable resources we offer. To streamline and simplify customer interactions, we have enhanced our website to provide easy access to our solutions, effectively linking customers to our robust network, one of the strongest and most reliable in the market, processing billions of customer's requests," said Shachar Daniel, Chief Executive Officer of Alarum.

08:36 EDT VEON board, management delegation visit Ukraine - VEON sent a senior delegation to Ukraine consisting of members of the VEON Board and Management. The delegation will visit Kyiv and Lviv, meeting with Kyivstar employees, Kyivstar's community support projects, government officials and representatives of diplomatic missions. The delegation's visit follows VEON's announcement on 9 October 2023 that it has closed the sale of its Russia operations and completed its exit from Russia - one of the most significant corporate exits given VEON's public listing and the relative size of the asset. VEON had committed USD 600 million to Ukraine's recovery and reconstruction over the next years during the "Ukraine Recovery Conference" in London in June. VEON is the parent company and the sole owner of Kyivstar, the largest telecoms operator in Ukraine, that serves 25 million customers and has kept Ukraine connected through extremely challenging conditions. Headquartered in Amsterdam, the Netherlands, VEON is a Nasdaq- and Euronext Amsterdam-listed company with a global investor base that includes US, EU and UK individuals and institutions, and does not have a controlling or majority shareholder. VEON recently responded to speculation on Kyivstar ownership with a statement re-asserting that it is the sole and rightful owner of Kyivstar and that it intends to use all available avenues to preserve the rights of VEON and Kyivstar.

08:35 EDT Castlelake to provide $200M private structured financing solution to Oportun - Castlelake announced the entry into a new agreement whereby certain of Castlelake funds and affiliates, will provide a $200 million private structured financing solution to Oportun. Under the terms of the agreement, Oportun will use the funds to finance the origination of its personal loan products. The transaction follows a $400 million whole loan flow sale agreement between the two companies, through which Castlelake will acquire personal loan production originated by Oportun over the next 12 months.

08:33 EDT Inpixon announces spin-off and merger of SAVES UK Business with Damon Motors - Inpixon announced that it has signed a definitive agreement under which its wholly owned subsidiary, Inpixon Ltd., a division of Inpixon's statistical analytics and visualization for engineering and sciences business based in the United Kingdom, will be acquired by private Canadian company, Damon Motors, a British Columbia company, and the maker of the acclaimed HyperSport electric motorcycle. The Damon HyperSport is expected to be one of the safest, smartest, and most powerful motorcycles available in the market. Damon concurrently announced that it has obtained approximately $85M in pre-production consumer reservations for its motorcycles. The enterprise value of Damon was ascertained by Inpixon's independent financial advisory firm to be within the range of $224M-$284M. This transaction is in addition to and independent of the pending merger transaction between Inpixon and XTI Aircraft, which remains on track for an anticipated closing this quarter. Inpixon has established October 24, 2023, as the record date for stockholders entitled to vote for the XTI Transaction at the special meeting, in lieu of the 2023 annual meeting of shareholders of Inpixon. Inpixon plans to contribute all the outstanding capital stock of Inpixon UK to Inpixon's newly formed British Columbia subsidiary, Grafiti Holding, followed by a spinoff of all the outstanding capital stock of Grafiti owned by Inpixon to the holders of Inpixon's outstanding capital stock, and certain other securities as of a record date to be determined. Following the merger between Grafiti and Damon, holders of Grafiti Shares, including Inpixon Securityholders and management holding Grafiti Shares immediately prior to the closing of the Business Combination, are anticipated to retain approximately 18.75% of the outstanding capital stock of the combined company determined on a fully diluted basis, which includes up to 5% in equity incentives, which may be issued to Inpixon management. Inpixon will also purchase a convertible promissory note from Damon in the principal amount of $3 million and warrants to purchase common shares of Damon for an aggregate purchase price of $3 million. Upon the closing of the Business Combination, the Damon Note and Warrants will be exchanged for common shares of the combined company and warrants to purchase common shares of the combined company in accordance with the terms of the definitive agreements. No securities of Inpixon will be issued in connection with the Business Combination. Following the completion of the Business Combination, Inpixon UK and Damon will be wholly owned subsidiaries of Grafiti, Grafiti will adopt a new name to be determined by Damon, and the combined company will be listed on the Nasdaq Stock Market, subject to Nasdaq approval of an initial listing application. The transaction has been approved unanimously by the Boards of Directors of both Inpixon and Damon subject to necessary approvals and the satisfaction of customary closing conditions. Inpixon will retain its Industrial Internet of Things business line and continue to work towards the completion of the XTI Transaction. Inpixon believes that pursuing these opportunities will offer multiple opportunities for its shareholders to maximize the value of their investment in Inpixon.

08:32 EDT Imunon CSO to present at third International Vaccines Congress - IMUNON announces that Khursheed Anwer, Ph.D., IMUNON's executive vice president and chief science officer, will highlight the Company's vaccine development work at the 3rd International Vaccines Congress being held in Boston October 23-26. Dr. Anwer will present "A DNA-based Vaccine Technology Independent of Virus or Device," at 2:00 p.m. Eastern time on October 23rd. His presentation describes the multiple advantages of the Company's PlaCCine modality over current commercial vaccine platforms, including more durable antigen expression and T-cell responses versus protein and mRNA vaccines. In addition, preclinical studies show that PlaCCine elicits better antibody response kinetics following a single dose and demonstrates better shelf-life of at least 12 months at 4 degrees C and at least two weeks at 37 degrees C, thus offering superior commercial handling and distribution properties versus mRNA vaccines as well as greater manufacturing flexibility. Compared with viral or other DNA vaccines or protein vaccines, PlaCCine vaccines have advantages in T-cell responses, safety, compliance and manufacturing flexibility. The presentation may be viewed on the Company's website in the Scientific Presentations section here. The presentation highlights immunogenicity data and the development status of IMNN-101, the Company's lead PlaCCine clinical candidate. IMNN-101 is designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant in accordance with the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee's June 2023 announcement of the framework for updated COVID-19 doses. IMUNON is targeting the first quarter of 2024 for submitting an Investigational New Drug application to the FDA and enrolling the first subject in a Phase 1 trial in April 2024, with rapid advancement into a Phase 2 trial by mid-2024. The presentation also describes the versatility of the PlaCCine modality, demonstrating the activity against Marburg and influenza viruses in collaboration with the Wistar Institute, and activity against Lassa virus being evaluated at the NIH/NIAID.

08:30 EDT Blink Charging installs electric vehicle charges at five McDonald's locations - Blink Charging (BLNK) announced the installation of Level 2 Blink IQ200 electric vehicle chargers at five restaurant locations throughout Puerto Rico. The installation was marked by a launch event providing EV drivers with free charging at select locations. Customers can now charge their EVs while they dine-in at the following locations: Montehiedra, Las Cumbres, Mayaguez Terrace, Ponce by Pass, and Fajardo. The installation of charging stations by Arcos Dorados, the largest independent McDonald's (MCD) franchisee in the world, and Blink aims to promote the adoption of electric vehicles in Puerto Rico. The agreement further establishes Blink's presence in the Latin American market. To date, Blink has successfully sold or deployed chargers across eight countries in LATAM since entering the market in 2020. EVs are expected to continue to grow in demand throughout Latin America, with a forecasted 5.4 million EVs on roads in the region by 2030.

08:27 EDT DSS files registration statement on Form S-1 - DSS has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of the Company's wholly-owned subsidiary, Impact Biomedical. DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions. The Company has engaged Aegis Capital as the exclusive placement agent for the registered direct offering. A registration statement on Form S-1 relating to these securities has been filed with the SEC and has yet to become effective.

08:25 EDT Inpixon trading halted, news pending

08:23 EDT iCAD to sell brachytherapy business line Xoft to Elekta for $5.5M - iCAD, Inc. (ICAD) announced that Elekta (EKTAY) has agreed to acquire Xoft, a subsidiary of iCAD, Inc. for approximately $5.5 million and assumed liabilities. Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023. By acquiring the Xoft Axxent Electronic Brachytherapy, Elekta will be able to offer electronic brachytherapy technology to provide expanded access to treatment for a range of cancers. Xoft's unique technology provides targeted cancer care expertly tailored to meet patients' personalized needs. The carefully designed Xoft eBx System empowers physicians with full confidence to precisely and effectively treat cancer and enable patients to live healthy, high-quality lives. The versatile Xoft eBx System utilizes breakthrough electronic brachytherapy technology to provide expanded treatment options for a range of cancers. With the Xoft System, highly focused therapeutic radiation of the disease target is possible in a minimally shielded setting, while sparing surrounding healthy tissue. The Xoft System is FDA cleared and CE marked, installed in more than 120 sites in 16 countries around the world and licensed in a growing number of countries for the treatment of cancer anywhere in the body. The Xoft technology is supported by a growing body of evidence for the treatment of early-stage breast cancer, non-melanoma skin cancer, gynecological cancers, and brain cancers. Emerging applications include colorectal, prostate, and pancreatic cancers. The Elekta solutions are used in more than 120 countries and through its global network, the Xoft technology will now be able to reach more patients in need of personalized, precision radiation therapy. The company will provide further updates on the transaction and its impact on cash, balance sheet and operations during its third quarter earnings call. Craig-Hallum Capital Group served as advisor to iCAD for this transaction.

08:20 EDT NewAmsterdam announces appointment of Somaiya as CFO - NewAmsterdam Pharma Company announced the appointment of Ian Somaiya as Chief Financial Officer, CFO. Somaiya is an established healthcare executive with extensive financial and operational expertise, including over two decades of experience on Wall Street as a prominent biotechnology research analyst. Somaiya most recently served as CFO and Chief Business Officer of Elucida Oncology.

08:19 EDT AMG acquires minority equity interest in Ara Partners, terms not disclosed - AMG acquired the minority equity interest in Ara Partners previously held by Capital Constellation, an investment platform managed by Wafra Inc., and certain of its affiliated investment vehicles. Ara Partners is a global private markets firm that invests in the transition to a lower-carbon economy, through investments in companies offering scalable technologies, products, or services that address critical issues of decarbonization across a range of essential industries. Founded by co-Managing Partners Charles Cherington and Troy Thacker, and with a senior management team averaging more than twenty years' experience, Ara Partners' industry, operating, and technical expertise enables collaboration with portfolio companies to bring decarbonization products and services to market efficiently. With approximately $5 billion in assets under management, Ara Partners has generated growth through strong investment performance as demand accelerates for industrial decarbonization solutions to achieve carbon emission reduction goals. The terms of the transaction were not disclosed. Ara Partners' management team will continue to direct the firm's day-to-day operations.

08:17 EDT ImmunoPrecise Antibodies provides update on recent share movement - ImmunoPrecise Antibodies provided an update on its overall growth strategy, particularly in light of recent market developments. IPA remains committed to expanding its contract research organization, or CRO, capabilities and leveraging technology to drive innovation and efficiency. The pioneering work at IPA's subsidiary, BioStrand, reinforces IPA's commitment to investing in cutting-edge biotechnology solutions to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. IPA provides specialized full-service antibody discovery, development and through a BioStrand's integrated platform, designed to enhance customers' drug discovery and development, has begun its limited release through a phased rollout strategy spanning the coming year. The company is currently charging as a fee-for-service with a planned roll-up to a Software as a Service, or SaaS, offering. IPA's first quarter fiscal year 2024, which ended July 31, 2023, reported a record 21.3% increase in revenue compared to the same period last year, but also witnessed IPA's protein manufacturing facility leverage its expanded capabilities, marking a 44% growth year over year. In addition, as a testament to a focus on shareholder value, IPA achieved a reduced quarterly burn to $1.6M Canadian dollars. IPA's focus on operational optimization while continuing to invest in sustainable growth continues in fiscal 2024. IPA does not believe the recent drop in stock price matches the value creation it is building with its growth strategy.

08:14 EDT 4D Molecular receives EMA PRIME designation for 4D-150 - 4D Molecular Therapeutics announced that the European Medicines Agency, EMA, has granted Priority Medicine, PRIME, designation for the investigational genetic medicine candidate 4D-150 for intravitreal treatment of wet age-related macular degeneration. PRIME designation is granted by the EMA to enhance support for the development of medicines that target an unmet medical need and offers the opportunity to accelerate review of the marketing applications to bring such medicines to patients sooner. The designation follows positive interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile. "We are thrilled that the EMA has awarded PRIME designation to intravitreal 4D-150," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "We believe this designation, which is only awarded to one-quarter of applications, validates the promising clinical data to date with 4D-150 in wet AMD patients and the potential to offer major therapeutic advantages over existing treatments. We are efficiently advancing 4D-150 development for treatment of both wet AMD and DME patients, both of which represent large market opportunities. This designation enables enhanced support from the EMA and provides the potential for expedited regulatory review."

08:13 EDT Bit Digital launches new AI business, procures NVIDIAH100 GPUs - Bit Digital launched Bit Digital AI, a new business line that will provide specialized infrastructure to support generative AI workstreams. The company has commenced Bit Digital AI operations by signing a binding term sheet with a customer to support their GPU-accelerated workloads. Under the agreement, Bit Digital will provide the customer with rental services for a minimum of 1,024 GPUs and a maximum of 4,096 GPUs. The total number of GPUs, contract length, and corresponding unit pricing will be determined upon signing the master service agreement. Bit Digital has agreed to purchase 132 FusionOne HPC from xFusion Digital Technologies, a global provider of digital infrastructure and services, for approximately $35M. The GPUs are expected to be delivered to the company by the end of 2023 and will be deployed at a Tier-3 datacenter. Bit Digital intends to finance the purchase with a mix of cash on hand, digital assets on the balance sheet, new equity issuance, and potentially equipment financing. Bit Digital has entered into a binding term sheet to provide cloud-based GPU resources to a customer with an initial contract duration spanning one to three years. For the minimum 1,024 GPUs, Bit Digital expects the contract to generate between approximately $23M and $27M in annual revenue. The maximum contract value for 4,096 GPUs with a three-year contract term exceeds $250M worth of revenue. Revenue generation is expected to begin in January 2024, and the contract is expected to contribute substantially higher margins than the Company's existing business operations. Bit Digital will source additional GPUs in the event the finalized contract exceeds the minimum 1,024 figure and expects to be able to take delivery of such additional GPUs during fiscal Q1 2024.

08:12 EDT ABM completes rollout of proprietary ABM EV Charging Network - ABM has completed the rollout of its proprietary ABM EV Charging Network, powered by its cloud-based ABM EV OS software in collaboration with Noodoe. Further elevating ABM's comprehensive single-source EV infrastructure solutions, this network will unlock personalized customer experiences while improving EV charger uptime. Amid a recent nationwide decline in driver satisfaction with public Level 2 charging, facility owners and operators across industries have been challenged to provide new solutions that recognize the importance of service, maintenance, and driver experience when installing and maintaining public EV chargers. A recent report by J.D. Power indicated roughly one in five public charging attempts fail, leading to driver frustration and dissatisfaction. To combat this trend, ABM is proud to announce the nationwide roll out of its EV Charging Network to pair with its other customized turnkey solutions for virtually every commercial application, allowing for the design and implementation of the right EV strategy. This comprehensive approach encompasses charger equipment, installation, maintenance, and upgrades, ensuring a seamless and reliable EV charging experience for both facility owners and drivers.

08:11 EDT Sysco awarded contracts for commercial driving testing in Florida, Texas - Sysco Corporation has been awarded contracts that allow its Central Florida and North Texas sites to become full-service Commercial Driver's License test sites. Together with its locations in Baltimore and Denver, a total of four Sysco sites have achieved this designation. In addition, all new delivery partners attend Sysco's Operations Academy to ensure a positive onboarding experience and learn the "Sysco Way" of operating safely and providing excellent customer service. Sysco Central Florida recently tested its first cohort of students and achieved a 100% pass rate. Following licensure, they will begin their Sysco career as Delivery Partner Trainees at their home site. Sysco North Texas will test their first cohort of students in November.

08:10 EDT Genasys announces New Hampshire DOS division selects Genasys Protect - Genasys announced that the New Hampshire Department of Safety's Division of Emergency Services and Communications, who manages statewide emergency messaging, has replaced its emergency notification system with Genasys Protect to keep its residents and visitors informed of critical public safety messaging from the state as well as local municipalities and severe weather-related notifications.

08:09 EDT Amazon's CCU and Prada collaborate to help get a counterfeiter's guilty plea - Amazon's Counterfeit Crimes Unit (CCU), the Prada Group, and other luxury brands collaborated to provide information and evidence to Chinese law enforcement, which resulted in a counterfeiter's guilty plea to crimes related to the sale of counterfeit luxury products.This is a unique and landmark case in the fight against counterfeiters and a turning point for Intellectual Property rights owners. The plea represents a rare instance where a criminal referral from the CCU resulted in a criminal judgment primarily based on the evidence of overseas counterfeit sales records and fulfillment center inventory records outside of China, and not on seized counterfeit products..."The guilty plea is a significant win for Amazon's CCU, but more importantly it's a win for all of those who share our commitment to tackling the industry-wide issue of counterfeiting," said Kebharu Smith, director of Amazon's CCU. "This successful result would not have been possible without the collaboration with law enforcement and luxury players such as the Prada Group. We are grateful for their support and look forward to continuing to take the fight to counterfeiters."

08:08 EDT PDS announces preliminary study results of subset of patients in VERSATILE-002 - PDS Biotechnology announced immune response data from a preliminary analysis of a subset of patients in VERSATILE-002, the Phase 2 clinical trial evaluating the safety and efficacy of PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA in patients with human papillomavirus 16-positive recurrent or metastatic head and neck squamous cell carcinoma, HNSCC. The data presented during the European Society for Medical Oncology Congress 2023 provided preliminary insight to the pre-existing immune responses in advanced HPV-positive HNSCC patients and potential changes to the immune profile after treatment. "Generation of multifunctional, anti-tumor T cells with the relevant cytokine and chemokine profiles are necessary for effective long-term control of tumor growth and clinical outcomes. This initial study focused on understanding the immunological profile of advanced head and cancer patients in the blood," said Kevin Harrington, PhD, Professor of Biological Cancer Therapies, The Royal Marsden. "This preliminary study suggests that PDS0101 may promote a TH1 predominant cytokine profile as well as induction of important T cell activating chemokines. Such studies could be helpful in providing further insight into how PDS0101 in combination with KEYTRUDA alters T cell cytokine and chemokine profiles to promote improved clinical outcomes." Highlights of the analysis include: combination of PDS0101 and KEYTRUDA appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity; Combination of PDS0101 and KEYTRUDA(R) resulted in increased polyfunctionality reflected in T cells expressing 5 or more cytokines. Increased polyfunctionality is typically associated with enhanced killing function and anti-tumor activity.

08:07 EDT Franco-Nevada: Cobre Panama mining concession contract enacted into law - Franco-Nevada is pleased to announce that it has been advised by its partner First Quantum Minerals that, on October 20, 2023, Law 406, which approves the refreshed mining concession contract for the Cobre Panama mine, was enacted into law in Panama. First Quantum noted that the enactment of Law 406 marks the final step in revising the legal framework for the Cobre Panama mine.

08:06 EDT Super League Enterprise presents at Esports and Gaming Business Summit - Super League announced its participation in the Esports and Gaming Business Summit 2023. The company will be prominently represented on two dynamic panel presentations. Matt Edelman, President and Chief Commercial Officer of Super League, will join a panel of industry leaders and share his expertise in a lively discussion about Using Esports and Gaming to Reach Gen Z. Moderated by Brag House CEO and Chairman Lavell Juan, Matt will be joined by Gary Wolf, US Account Director, The McDonald's Division, The Coca-Cola Company, former Head of Marketing and Content at TSM, SM Lahti, and United Esports Founder and CEO, Felix LaHaye. Together they will explore the dynamic world of gaming that has captured the hearts and attention of Gen-Z consumers and will discuss where they've found success in getting a generation so used to free content to invest in their brands. In a separate panel, Zach Hahn, SVP of Partnerships at Super League will be moderating a conversation about interactive and immersive spaces that make up the metaverse, where young consumers spend a significant amount of time. Joining Zach on stage in a panel titled The Future of Brand Engagement: Why immersive gaming platforms matter and need to be in your marketing plan will be Justine Higueras, Director of Emerging Partnerships at Roblox, Samantha Lim, SVP of Gaming Strategy and Innovation at Publicis, and Mason Bates, Head of Gaming and Esports at Verizon. In this session, panelists will explore how to capitalize on emerging trends in digital experience platforms like Roblox, how to create and sustain a meaningful presence, and share the latest strategies and tactics to produce immersive content that resonates with a brand's target audience. They'll also discuss why this emerging social media channel needs to be an integral part of everyone's media mix, both to stay ahead of the competition and to be at the forefront of where brands and consumers will form the strongest relationships in the coming decade and beyond.

08:05 EDT Aspira Women's Health establishes new clinical advisory board - Aspira Women's Health has established a Clinical Advisory Board as an element of its overall mission to develop and distribute high-impact diagnostic tools for gynecologic disease. The Clinical Advisory Board will provide clinical input and guidance throughout the development of the Company's portfolio of products. Each member of the board is a recognized thought-leader with deep clinical expertise in gynecologic health. The Clinical Advisory Board, which will be chaired by Dr. Twiggs, includes the following initial members: Levi S. Downs, Jr., M.D., M.S., Medical Director for Gynecologic Oncology, Park Nicollet Health System, Methodist Hospital; Nisha Garg, M.D., M.S., FACOG, Gynecologic Surgeon, Arizona Gynecology Consultants; Tamika Sea, M.D., FACOG, Founder and Owner, Advanced Women's Care Center

08:05 EDT TC Biopharm submits IND application to FDA for use of TCB-008 to treat AML - TC BioPharm announced submission of an Investigational New Drug application to the U.S. FDA for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008, an allogeneic unmodified gamma delta t-cell, is the company's lead product and is currently in Phase 2b trials in the U.K. for the treatment of AML. The IND application leverages pioneering research on the use of Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008 has been designated Orphan Drug Status in the treatment arena of AML previously.

08:03 EDT Medtronic receives FDA approval for extravascular defibrillator - Medtronic has received U.S. FDA approval for the Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. The Aurora EV-ICD system is the first-of-its-kind to provide the life-saving benefits of traditional, transvenous ICDs with a lead (thin wire) placed under the breastbone, outside of the heart and veins. The Aurora EV-ICD delivers lifesaving defibrillation, anti-tachycardia pacing, and back-up (pause-prevention) pacing therapies via a device similar in size, shape, and longevity to traditional, transvenous ICDs.

07:48 EDT Glass Lewis recommends Abcam shareholders vote for Danaher acquisition - Abcam(ABCM) announced that leading independent proxy advisor, Glass Lewis, recommended that Abcam shareholders vote "for " Danaher's (DHR) proposed acquisition of Abcam ahead of its shareholder meetings on November 6. Alan Hirzel, Chief Executive Officer of Abcam, said: "Following the publication of Glass Lewis's recommendation on October 21, we're pleased that both of the world's leading proxy advisors support our board's unanimous recommendation that shareholders vote for the proposed sale to Danaher. We are confident this transaction is in the best interests of Abcam and its shareholders, and will deliver an excellent outcome for Abcam's employees and customers. We strongly urge all Abcam shareholders to follow the recommendation of our board, ISS and Glass Lewis and vote for this transaction." In making the recommendations, Glass Lewis stated in their October 21 report: "[We] believe the premium valuation and certainty of value provided by the Scheme Consideration should represent a fairly compelling proposition to most of the Company's shareholders..."

07:44 EDT Camping World set to acquire Travelcamp RV to add 12 locations, no terms - Camping World Holdings announced that it is set to acquire Travelcamp RV. The transaction would add 12 locations across Florida, Georgia, North Carolina, South Carolina, and Texas. The acquired locations are expected to close and transition to Camping World over the next 90 days. Marcus Lemonis, Chairman and CEO of Camping World commented, "This acquisition establishes our presence in new markets and strengthens our position in existing markets. We were attracted to Travelcamp's focus on affordably priced RV segments, particularly with two top manufacturers. After closing, we anticipate these locations to be primarily stocked with either Thor or Forest River products." Mr. Lemonis continued, "We continue to be focused on our goal to increase our dealership count to over 320 locations over the next five years, through a combination of acquisitions, new store openings, and manufacturer exclusive locations."

07:38 EDT Merus announces Zeno interim data from Phase 1/2 eNRGy trial - Merus announced interim clinical data, as of a July 31, 2023 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program of the bispecific antibody zenocutuzumab in patients with neuregulin 1 fusion cancer presented by Principal Investigator, Dr. Alison Schram* of Memorial Sloan Kettering Cancer Center at the European Society for Medical Oncology, ESMO, Congress 2023. Observations in the presentation include: As of July 31, 2023 data cutoff date, 105 patients with NRG1+ NSCLC were treated with Zeno. 78 patients with measurable disease were treated by February 13, 2023, allowing for the potential for greater than or equal to 24 week follow-up, and who met the criteria for the primary analysis population. 37.2% overall response rate per RECIST v1.1 by investigator assessment; 61.5% clinical benefit rate; 14.9 months median duration of response and 20 of patients were continuing treatment as of the data cutoff; Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive pancreatic ductal adenocarcinoma. Observations in the presentation include: As of July 31, 2023 data cutoff date, 44 patients with NRG1+ PDAC were treated with Zeno. 33 patients with measurable disease were treated by February 13, 2023, allowing for the potential for greater than or equal to 24 weeks follow-up, and who met the criteria for the primary analysis population. 42.4% ORR per RECIST v1.1 by investigator assessment; 1 patient achieved a complete response, and 13 patients achieved a partial response; 72.7% clinical benefit rate; 82% experienced tumor reduction; Of 21 patients evaluable for CA 19-9 levels, 78% showed a greater than or equal to 50% decrease in CA 19-9 values from baseline; 9.1 months median DOR; and 6 patients were continuing treatment as of the data cutoff. Safety findings from both presentations: Zeno demonstrated a well-tolerated safety profile among the 189 NRG1+ cancer patients who were treated with 750 mg Q2W monotherapy, with only 6% of patients experiencing related grade 3-4 toxicities.

07:36 EDT Starbox Group launches image-to-video feature in StarboxAI - ViPro - Starbox Group announced the addition of an image-to-video feature in its StarboxAI - ViPro module. This tool harnesses the power of AI to convert static images into dynamic videos, accelerating video production for promotional and marketing materials. The StarboxAI - ViPro's image-to-video feature enables users to input a sequence of images and accompanying text descriptions. The AI algorithm then processes these inputs and synthesizes them into a coherent video sequence, complete with transitional effects and timing that matches the context and theme of the input.

07:34 EDT INVO Bioscience and NAYA Biosciences sign merger agreement - INVO Bioscience and NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, have entered into a definitive merger agreement for INVO to acquire NAYA Biosciences in an all-stock transaction. NAYA Biosciences' shareholders will receive 7.3333 shares of INVO for each share of NAYA Biosciences at closing, for a total of approximately 18,150,000 shares of INVO. Following the closing of the Merger, the combined company is expected to operate under the name "NAYA Biosciences". Daniel Teper, currently CEO of NAYA Biosciences, will be named Chairman & CEO of the combined company. The merger - which remains subject to certain closing conditions including shareholder approval, an estimated $5M or more in interim private financing in INVO at a premium of INVO's market price at time of financing, and a private offering by the combined company at a target price of $5.00 - values INVO at $12,373,780 and NAYA at $90,750,000. Subject to the Interim PIPE, post-transaction and prior to the private offering, INVO and NAYA shareholders will own approximately 12% and 88%, respectively, of the combined company. Following the merger, NAYA Biosciences plans to operate as a NASDAQ-listed group of companies dedicated to increasing patient access to treatments in oncology, fertility and regenerative medicine. NAYA Oncology has acquired two clinical-stage bispecific antibody assets for the treatment of Hepatocellular Carcinoma and Multiple Myeloma from Cytovia Therapeutics, a biopharmaceutical company focused on immune cell engager bispecific antibodies and gene-edited cell therapeutics, for a consideration in cash and shares at an agreed price of $5 in the merged company. In connection with the Merger, INVO will issue to NAYA more than 80% of its common stock, effectively resulting in a change of control. The Merger has been unanimously approved by the board of directors of each company and is expected to close in Q4. The Board of Directors of the combined company will have six directors nominated by NAYA and one director nominated by INVO.

07:33 EDT Amesite enters partnership with Wayne State University Graduate School - Amesite announces it has partnered with The Graduate School of Wayne State University to deliver graduate-level programs. "Our technology enables us to deliver streamlined, no-risk purchase offers, that enable Customers to offer a remarkably wide range of learning programs on their branded platforms. We're redefining the pace and efficiency with which organizations can deliver eLearning." said Amesite CEO, Dr. Ann Marie Sastry.

07:12 EDT Oncolytics presents positive updated Phase 1/2 pancreatic cancer data - Oncolytics announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma at the European Society for Medical Oncology meeting in Madrid, Spain. "We are very pleased to share such positive and consistent data on pelareorep from the PDAC arm of the GOBLET study, including an impressive overall response rate, 7.2 months of median progression-free survival, interim median overall survival of 10.6 months, and expansion of both pre-existing and new T-cell clones. These data build upon results from previous studies showing the clinical benefit of pelareorep combination therapy in PDAC and support the decision to move to a licensure-enabling study in pancreatic cancer," said CEO Matt Coffey. "...The data we are presenting at ESMO provide a solid foundation as we advance our pancreatic cancer program through the Precision Promise Phase 3 trial in this indication." The treatment combination has been well tolerated with no safety concerns.

07:12 EDT NextSource Materials announces first bulk shipment oof SuperFlake - NextSource Materials announced it has made its first bulk container shipment of SuperFlake graphite from the Company's Molo Mine in Madagascar. This first shipment of Molo SuperFlake graphite has been sent to the Company's downstream technical partner's Battery Anode Facility to be processed into spheronized, purified graphite that will then be further processed into coated SPG as part of large scale, multi-step verification tests being conducted by automotive EV supply chains in South Korea and Japan. The Company expects to receive its first series of verification test results starting in December 2023. NextSource is intent on becoming a vertically integrated global supplier of graphite anode material with plans to construct, in stages, multiple BAFs capable of producing CSPG at commercial scale in key jurisdictions. Through long-term collaborative partnerships secured with our downstream technical partners, NextSource will leverage its exclusive access to the partner's well-established and best-in-class processing IP for SPG, currently used in multiple OEM supply chains and an EV supply chain-verified coating IP to produce CSPG. The exact same processing equipment, flow sheet and production methods used by the downstream technical partner in their BAFs, will be replicated and deployed in the Company's planned BAFs. The Company is also pleased to announce it has completed commissioning and achieved full operations of its solar and battery hybrid power plant at Molo. The Solar Hybrid Plant is owned and operated by CrossBoundary Energy under a 20-year power purchase agreement and comprises a 2.69 MWp solar photovoltaic array combined with a 1.37 MWh battery energy storage system, and a 3.1 MW thermal generator plant. The entire PV array, incorporating 4,902 photovoltaic panels covering an area of 12,663 square metres has been fully integrated with the BESS.

07:10 EDT Eledon Pharmaceuticals appoints Katz as CMO - Eledon Pharmaceuticals announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer, CMO, with responsibility for leading the company's clinical development programs. Dr. Katz is an experienced transplant surgeon with significant clinical development experience. Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis' xenotransplantation programs.

07:10 EDT Methes Energies announces results of lifecycle assessment of bio-based lubricant - Methes Energies International announced the results of a lifecycle assessment that demonstrated and concluded the environmental benefits when comparing the use of a bio-based vs a conventional lubricant, motor or engine oil. The additional benefits of minimizing the use of "non-renewable" resources through the use of plant based raw materials have grown over recent years due to a major emphasis being put on global warming potential and a growing need to reduce the use of valuable and depleting resources. A Life Cycle Assessment was conducted to provide an environmental analysis of the benefits of a bio-based/biodegradable lubricant, B2 BiOil, compared to mineral based counterparts for bar & chain, 5W-30 and 2-cycle motor and engine oils. An LCA provides an analysis of the environmental impacts of each lifecycle stage of the product...from the extraction of raw materials to the disposal of generated waste through landfill disposal and incineration. It's a "cradle to the grave" assessment; and, therefore, includes the lifecycle impacts of raw material planting, harvesting, farming and/or extraction all the way to consumer or customer consumption, recycle, lost in use and disposal of these base oils The results confirmed that Methes' bio-based lubricants had a 29-67% lower carbon footprint than their conventional alternatives. In terms of real world examples, the reduction in impact created by the replacing of just 1% of conventional motor oil consumption in the USA with bio-based lubricants is 626 metric tonnes CO2, which is the equivalent of driving 1,508,447 miles in an average passenger vehicle. In conclusion, replacing 1% of conventional motor oil consumption in the USA with b2 biOil would save around 137 million pounds of carbon dioxide a year. Please visit website for complete details of the lifecycle assessment of bio-based versus conventional oils.

07:09 EDT Bitfarms reaches 240 MW, 6.3 EH/s as Baie-Comeau energizes initial phase - Bitfarms fully energized the first phase of its farm in Baie-Comeau, Quebec, increasing its total operating capacity to 240 MW and its hashrate to 6.3 EH/s. "By fully energizing Baie-Comeau, we increased our corporate operating capacity with cost-effective and clean hydro power and achieved our 6.3 EH/s goal," said Bitfarms CEO Geoff Morphy. "This efficient facility leverages our operating and design expertise. We will continue to manage our balance sheet prudently to be positioned to capture growth opportunities both before and after the next Bitcoin halving, expected in mid-April 2024." Bitfarms acquired Baie-Comeau in July 2023, with the plan to reach 11 MW by the end of Q3 2023 and add another 11 MW when power is made available, which is expected in 2H 2024.

07:07 EDT Brookfield appoints Sir Ron Kalifa as head of financial infrastructure - Brookfield Asset Management announced the appointment of Sir Ron Kalifa as Vice Chair and Head of Financial Infrastructure investments. Ron brings a wealth of experience to his role at Brookfield, including over two decades of building and transforming businesses in the global payments space, and as a Non-Executive Director of the Bank of England's Court of Directors. Brookfield's financial infrastructure strategy focuses on identifying opportunities in digital assets and services that form the backbone of the global financial economy. The strategy typically seeks mature, high-quality companies that are integral components of the financial ecosystem and leverages Brookfield's expertise in growing businesses through operational value creation. Brookfield has invested or committed approximately $5 billion in financial infrastructure companies, including Network International1 and Magnati. The addition of Sir Ron Kalifa to lead this strategy will allow Brookfield to increase our footprint in this critical area of focus.

07:06 EDT Enthusiast Gaming announces intention to voluntarily delist from Nasdaq - Enthusiast Gaming Holdings announced that it has notified the Nasdaq Stock Market of its intention to voluntarily delist its common shares from Nasdaq. Shares will continue to trade on the Toronto Stock Exchange. As previously announced in its press release dated May 4, 2023, the Listing Qualifications department of Nasdaq approved the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). Although the Company has until October 30, 2023, to regain compliance with the Bid Price Rule, after careful consideration, the Company has evaluated the benefits and costs of continuing its listing on Nasdaq and has concluded that it is appropriate to voluntarily delist from Nasdaq. The Company estimates that it incurs over $2 million of annual costs in connection with maintaining a dual listing, which expenses are expected to increase significantly in future years due to increasing compliance and other regulatory requirements. With the Shares concurrently trading on the TSX, the Company believes the relatively high insurance, listing, reporting, legal and compliance costs that are associated with a continued U.S. stock exchange listing, as well as the administrative burdens and requirements associated with maintaining a dual listing, are not justified at this time. The Company has also concluded that a reverse split of the Company's Shares in order to come into compliance with the Bid Price Rule is not in the best interest of shareholders. The Company intends to file a Form 25 with the U.S. Securities and Exchange Commission on or about October 30, 2023, which Form would become effective 10 days following filing thereof, resulting in the delisting of the Shares from Nasdaq on or about November 9, 2023.

07:04 EDT Golden Heaven announces 10% traffic growth during Chinese holidays - Golden Heaven announced that its five operational amusement parks attracted approximate 86,000 visitors during the 2023 Mid-Autumn Festival and National Day holidays, spanning from September 29 to October 6. Despite the temporary closure of Mangshi Jinsheng Amusement Park, which was a strategic decision to explore the future business development of such park, and the impact of rainy weather at some park locations during the Holidays, the number of visitors at the five amusement parks in operation continued to show growth, marking a 10% year-on-year increase and 146% growth over the 2023 Labor Day holiday in China.

07:04 EDT Unicycive Therapeutics reaches alignment with FDA on path to OLC NDA - Unicycive Therapeutics announced the Company has reached alignment with the U.S. Food and Drug Administration on the path forward for Oxylanthanum Carbonate and on the overall package requirements to file a New Drug Application. As reported in June, in the pre-NDA package shared with the FDA, the Agency requested clinical data in patients to proceed with the filing. Recently, during a Type C meeting with the FDA, the Company and the Agency reached an agreement on the overall data package requirements to file the NDA including clinical data, preclinical data, and CMC. As a reminder, Unicycive intends to file the OLC NDA utilizing the 505(b)(2) regulatory pathway to reference the currently approved drug, Fosrenol. In the Type C meeting, plans were confirmed with the FDA for the pivotal clinical trial. The Agency agrees with the Company's study design of 60 participants to be evaluated for 4 weeks on OLC once participants are titrated to clinically effective doses. The study is designed to evaluate tolerability and the event rate for discontinuation; therefore, there is no statistical analysis required to demonstrate efficacy. No other clinical study is required. We believe that results from this pivotal trial will enhance our safety data package from preclinical studies, and the efficacy data is referenced with Unicycive's previously disclosed bioequivalence study. As of June 30, 2023, Unicycive's cash position was reported as $18.8 million which is expected to last into the second half of 2024 including the ability to start and complete the pivotal clinical trial. The planned clinical trial is expected to be an open-label, single-arm, multicenter, multidose study to evaluate the tolerability of clinically effective doses of OLC in participants with chronic kidney disease (CKD) on dialysis. As a reminder, all approved phosphate binders, including Fosrenol, are administered to patients on a dose titration schedule based on the control of serum phosphate. In Unicycive's clinical trial, once participants have been titrated to a clinically effective dose with a serum phosphate range of less than or equal to5.5 mg/dL, they will be treated for four weeks to evaluate serum phosphate levels.

07:03 EDT Fisker lowers U.S. price for top-level Fisker Ocean Extreme - Fisker announced a price reduction for the Fisker Ocean Extreme, the top trim level of the all-electric SUV. In the US, Fisker is lowering the price of the Ocean Extreme trim by $7,500, to $61,499 from $68,999. This price change will go into effect immediately. Customers who have already ordered or purchased an Extreme will receive a $7,500 price adjustment. The Fisker Ocean Extreme has a 113 kWh battery pack and an EPA range of 360 miles, which is the longest range of any new electric SUV in its class 2.

07:02 EDT Mind Technology awarded contract in excess of $5M - Mind Technology announced that its Seamap unit has been awarded an order by PGS Geophysical AS to provide an ultra-high resolution 3-D seismic streamer system for PGS' new energy initiative. The value of the contract, which is expected to be delivered in calendar 2024, is in excess of $5M.

06:57 EDT Ryder to acquire Impact Fulfillment Services - Ryder entered into a definitive agreement in Q3 to acquire all of the outstanding equity of IFS Holdings, also known as Impact Fulfillment Services - IFS -. IFS specializes in contract packaging, contract manufacturing, and warehousing for some of the largest consumer brands in the U.S., primarily in the consumer packaged goods, retail, and healthcare industries. As part of the transaction, Ryder will acquire 15 operations across Florida, Georgia, Illinois, North Carolina, Ohio, Pennsylvania, Texas, Utah, and California. The transaction is expected to add approximately $250M in annual total revenue to Ryder's supply chain solutions business segment and be accretive to shareholders. Ryder and IFS expect to complete the transaction in early November, subject to satisfaction of antitrust approvals and customary closing conditions. Ryder plans to retain IFS' workforce of approximately 1,000 full-time employees. President of IFS Rob LeBaron will join Ryder as vice president of contract manufacturing and packaging. Founded 25 years ago, IFS specializes in contract manufacturing, contract packaging and assembly, display engineering, product launches, multichannel programs, and club store programs.

06:39 EDT Hope Bancorp announces strategic organization - Hope Bancorp announced a strategic reorganization designed to enhance shareholder value over the long term. Accordingly, the company realigned its structure around lines of business and product delivery channels, optimized its production capacity and reduced headcount. The restructuring is expected to generate over $40M in estimated annualized cost savings, largely related to the reduction in staffing, savings from a planned branch rationalization, subject to customary notices and approvals, and operational process improvements. The company expects to recognize one-time charges of approximately $12M in Q4 2023 related to the reorganization.

06:32 EDT Ault Inc. reports preliminary Q3 revenue exceeding $52.5M - Ault Alliance projects a total consolidated revenue of $190M-200M for the fiscal year ending December 31, 2023.

06:25 EDT AstraZeneca, Daiichi Sankyo's Enhertu approved in EU for certain NSCLC - AstraZeneca (AZN) and Daiichi Sankyo's (DSNKY) has been approved in the European Union as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer, or NSCLC, whose tumors have an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy, the companies announced.

06:09 EDT Bombardier announces seventh delivery of Global 6000 aircraft to U.S. Air Force - Bombardier recently celebrated the seventh delivery of a Global 6000 aircraft to the U.S. Air Force Battlefield Airborne Communications Node program at the company's Hartford Service Centre, in Connecticut. The BACN aircraft is a specialized communications platform, known in the USAF as the E-11A, that is part of a previously announced multi-year contract representing a potential total value of close to $465M. Bombardier has already delivered six Global aircraft to the BACN program under previous agreements. The USAF has the option to purchase an additional aircraft each year through 2026 under the 2021 contract.

06:08 EDT reAlpha announces effectiveness of registration statement - reAlpha Tech Corp. announces that its registration statement on Form S-11 was declared effective by the U.S. SEC on October 20, 2023. reAlpha anticipates that its common stock will begin trading on The Nasdaq Capital Market under the ticker symbol "AIRE" on October 23, 2023.

06:05 EDT Insulet's Omnipod 5 app for iPhone granted FDA 510(k) clearance - Insulet has received FDA 510(k) clearance for the Omnipod 5 App for iPhone, offering a tubeless automated insulin delivery system with full control from a compatible Android and iOS smartphone. Since its commercial launch in August 2022 in the U.S., the Omnipod 5 Automated Insulin Delivery System has included the option for smartphone control for customers using compatible Android devices. The Omnipod 5 Pod will soon be controllable from a compatible iPhone. The Omnipod 5 App for iPhone will launch first with the Dexcom G6 Continuous Glucose Monitoring System integration, with a full market release in 2024.

06:02 EDT Fortive to Acquire EA Elektro-Automatik for $1.45B - Fortive has entered into a definitive agreement to acquire EA Elektro-Automatik, a supplier of high-power electronic test solutions for energy storage, mobility, hydrogen, and renewable energy applications, for $1.45B in cash, net of $215M of tax benefits from Bregal Unternehmerkapital. The acquisition is subject to customary closing conditions and regulatory approvals and is expected to close in early Q1 2024. Fortive expects to finance the acquisition with available cash and debt financing. The acquisition is expected to be accretive to adjusted gross and operating margins and neutral to modestly accretive to adjusted diluted net EPS in FY24.

05:51 EDT Fanhua announces joint ventures with Asia Insurance - Fanhua announced a strategic partnership with Asia Insurance, a wholly-owned subsidiary of Asia Financial Holdings. Together, the two companies are forming two joint ventures: a life insurance brokerage company and an insurance technology company. Fanhua will be the majority shareholder of both joint ventures, with a 60% ownership stake in each. Both of the newly established joint ventures will be headquartered in Hong Kong.

05:41 EDT Philips sees FY23 comparable sales up 6%-7% - The company said, "Based on Philips' improved performance year-to-date, the strong order book, and the ongoing actions, the company is further raising the outlook for the full year 2023, although recognizing uncertainties remain in an increasingly volatile geopolitical environment. Philips now expects to deliver 6%-7% comparable sales growth and an Adjusted EBITA margin of 10-11% for the full year 2023, with free cash flow at the upper end of the target range of EUR 0.7-0.9 billion. This reinforces Philips' confidence in delivering on its three-year plan to create value with sustainable impact."

05:27 EDT Guardant Health announces initial results from Pegasus trial - Guardant Health announced that initial results from the Pegasus trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer. Results from the trial, which is an ISS study sponsored by IFOM ETS - the AIRC Institute of Molecular Oncology in Milan, Italy, and supported by Guardant Health, were presented today by study investigators at the ESMO Congress in Madrid, Spain. One of the first prospective studies using liquid biopsy, the Pegasus trial includes 135 patients recruited from 11 cancer centers in Italy and Spain. The study is assessing the feasibility of escalating or de-escalating adjuvant chemotherapy based on the presence or absence of minimal residual disease, or MRD, as indicated by circulating tumor DNA, or ctDNA, detected by the Guardant Reveal blood test at multiple timepoints. Patients with positive results receive standard chemotherapy, while patients with negative results receive a milder therapy that is associated with significantly less acute and chronic neurological toxicity compared to standard treatment. Liquid biopsy is repeated several times along the course of treatment to reveal opportunities to treat patients safely with lower toxicity regimens, identify therapeutic resistance, and tailor chemotherapy to be stronger when needed. Initial results show that 34% of patients with a liquid biopsy result after surgery had the cancer return, while only 10% of patients with a negative result experienced a relapse. Approximately 40% of patients converted from ctDNA-positive to ctDNA-negative after treatment, suggesting treatment efficacy of chemotherapy for some patients.

05:20 EDT iQIYI signs partnership letter of intent with TAT in Beijing - iQIYI has signed a strategic partnership letter of intent with the Tourism Authority of Thailand, or TAT, in Beijing at a ceremony attended by Thailand Prime Minister Srettha Thavisin, Governor of TAT Thapanee Kiatphaibool, iQIYI president of movies and overseas business group Yang Xianghua, as well as representatives from seven Chinese leading businesses Ant Group, Ctrip, Huawei, JegoTrip, Meituan, Spring Airlines and Sina News. With this strategic partnership, iQIYI and Tourism Authority of Thailand, or TAT, will work together actively in Thai language productions, collaboration and exchange of China-Thailand talents, as well as setting Chinese language productions in Thailand.

05:13 EDT Chevron to acquire Hess Corp. for $171 per share in all-stock transaction - Chevron (CVX) announced that it has entered into a definitive agreement with Hess Corporation (HES) to acquire all of the outstanding shares of Hess in an all-stock transaction valued at $53B, or $171 per share based on Chevron's closing price on October 20. Under the terms of the agreement, Hess shareholders will receive 1.0250 shares of Chevron for each Hess share. The total enterprise value, including debt, of the transaction is $60B.The Stabroek block in Guyana is an asset with cash margins and low carbon intensity that is expected to deliver production growth into the next decade. Hess' Bakken assets add another U.S. shale position to Chevron's DJ and Permian basin operations. The combined company is expected to grow production and free cash flow faster and for longer than Chevron's current five-year guidance. In addition, John Hess is expected to join Chevron's board of directors. The acquisition consideration is structured with 100% stock utilizing Chevron's equity. In aggregate, upon closing of the transaction, Chevron will issue approximately 317M shares of common stock. Total enterprise value of $60B includes net debt and book value of non-controlling interest. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the first half of 2024. The acquisition is subject to Hess shareholder approval. It is also subject to regulatory approvals and other customary closing conditions. The transaction price represents a premium of 10.3% on a 20-day average based on closing stock prices on October 20.